AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® in treating moderate to severe atopic dermatitis based on...

Related Keywords

United States ,Berlin ,Germany ,Japan ,Japanese ,Mudra Kapoor ,J Clin Dermatol ,Facebook ,Youtube ,Exchange Commission ,Allergan ,Abbvie Ltd ,Linkedin ,Twitter ,Instagram ,European Academy Of Dermatology ,European Academy ,Emergent Adverse Events ,Global Assessment ,Atopic Dermatitis ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Upadacitinib Through ,Moderate To Severe Atopic Dermatitis ,Clinical Trial ,Global Epidemiology ,Ann Nutr Metab ,Rev Dis Primers ,Adolescents With Uncontrolled Moderate ,Severe Atopic Dermatitis ,Term Efficacy ,Results Through Week ,Label Extension Trial ,Healthcare Claims Data ,Accessed August ,Markets ,